Sarah Boyce, President and CEO at Avidity Biosciences, Inc. (RNA), sold 14,387 shares at $72.45 ($1.0M) on 2026-01-21, disclosed to the SEC on 2026-01-23.
Scheduled sale ($1.0M) by President and CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $72.45 | 6,394 | $463K | 44.4% |
| 2 | $72.45 | 7,993 | $579K | 55.6% |
| Total | $72.45 avg | 14,387 | $1.0M | 100% |
| Filing → |
| RNA | SELL | 2025-08-29 | $1.2M | — | Filing → |
| RNA | SELL | 2025-03-21 | $2.0M | — | Filing → |
| RNA | SELL | 2025-01-23 | $595K | — | Filing → |